Lutetium-177 DOTATATE: A Practical Review

Keyphrases

• Neuroendocrine Tumor 100%
• Lutetium-177 (177Lu) 100%
• 177Lu-DOTATATE 100%
• Tyr3-octreotate 100%
• Tumor 50%
• Clinical Outcomes 50%
• Disease-free Survival 50%
• Somatostatin Receptor 50%
• Metastatic Disease 50%
• Histological Grade 50%
• Heterogeneous Groups 50%
• Promising Treatment 50%
• Toxicity Profile 50%
• Locally Advanced 50%
• Endocrine Tissues 50%
• Histological Differentiation 50%
• Treatment Standards 50%
• Octreotide 50%
• Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) 50%
• Peptide Receptor Radionuclide Therapy 50%
• NETTER-1 50%

Medicine and Dentistry

• Lutetium 177 100%
• Tetraxetan 66%
• Neuroendocrine Tumor 66%
• Neoplasm 33%
• Metastatic Carcinoma 33%
• Disease Free Survival 33%
• Somatostatin Receptor 33%
• Radionuclide Therapy 33%
• Octreotide 33%
• Gastroenteropancreatic Neuroendocrine Tumor 33%
• Peptide Receptor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Lutetium 177 100%
• Tetraxetan 66%
• Neuroendocrine Tumor 66%
• Neoplasm 33%
• Receptor 33%
• Disease Free Survival 33%
• Metastasis 33%
• Radioisotope 33%
• Somatostatin Receptor 33%
• Octreotide 33%
• Gastroenteropancreatic Neuroendocrine Tumor 33%